Vai direttamente al contenuto

Oncologia

Gestione dell’anemia

Farmaci stimolanti l'eritropoiesi

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (apre una nuova finestra)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Fonte‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Indicizzato‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (apre una nuova finestra)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (apre una nuova finestra)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Fonte‎: Acta Haematol 2007;117(3):162-7.

Indicizzato‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (apre una nuova finestra)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (apre una nuova finestra)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Fonte‎: Am J Hematol 2013;88(12):990-6.

Indicizzato‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (apre una nuova finestra)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (apre una nuova finestra)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Fonte‎: J Clin Oncol 2011;29(28):3791-7.

Indicizzato‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (apre una nuova finestra)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (apre una nuova finestra)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Fonte‎: Cancer 2012;118(3):848-55.

Indicizzato‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (apre una nuova finestra)

Management of anemia in cancer patients. (apre una nuova finestra)

Calabrich A, Katz A.

Fonte‎: Future Oncol 2011;7(4):507-17.

Indicizzato‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (apre una nuova finestra)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (apre una nuova finestra)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Fonte‎: BJU Int 2011;108(10):1582-7.

Indicizzato‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (apre una nuova finestra)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (apre una nuova finestra)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Fonte‎: J Clin Oncol 2010;28(13):2239-45.

Indicizzato‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (apre una nuova finestra)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (apre una nuova finestra)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Fonte‎: Br J Cancer 2011;105(9):1267-72.

Indicizzato‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (apre una nuova finestra)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (apre una nuova finestra)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Fonte‎: J Intern Med 2017;281(3):284-99.

Indicizzato‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (apre una nuova finestra)

How I treat cancer-associated anemia. (apre una nuova finestra)

Gilreath JA, Rodgers GM

Fonte‎: Blood 2020;136(7):801-13.

Indicizzato‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (apre una nuova finestra)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (apre una nuova finestra)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Fonte‎: Eur J Haematol. 2023 110(4):354-61.

Indicizzato‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (apre una nuova finestra)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (apre una nuova finestra)

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

Fonte‎: Int J Hematol 2015;102(4):401-12.

Indicizzato‎: PubMed 26323997

DOI‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 (apre una nuova finestra)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (apre una nuova finestra)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Fonte‎: Cancer 2013;119(1):107-14.

Indicizzato‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (apre una nuova finestra)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (apre una nuova finestra)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Fonte‎: J Natl Cancer Inst 2013;105(14):1018-26.

Indicizzato‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (apre una nuova finestra)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (apre una nuova finestra)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Fonte‎: Cancer Sci 2013;104(4):481-5.

Indicizzato‎: PubMed 23331490

DOI‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (apre una nuova finestra)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (apre una nuova finestra)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Fonte‎: Support Care Cancer 2012;20(1):159-65.

Indicizzato‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (apre una nuova finestra)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (apre una nuova finestra)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Fonte‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indicizzato‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (apre una nuova finestra)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (apre una nuova finestra)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Fonte‎: Oncologist 2010;15(9):935-43.

Indicizzato‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (apre una nuova finestra)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (apre una nuova finestra)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Fonte‎: Lung Cancer 2012;76(3):478-85.

Indicizzato‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (apre una nuova finestra)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (apre una nuova finestra)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Fonte‎: Eur J Haematol 2016;97(1):33-8.

Indicizzato‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (apre una nuova finestra)

Ferro per via endovenosa

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (apre una nuova finestra)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Fonte‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Indicizzato‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (apre una nuova finestra)

Intravenous iron in oncology. (apre una nuova finestra)

Auerbach M, Ballard H.

Fonte‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Indicizzato‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (apre una nuova finestra)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (apre una nuova finestra)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Fonte‎: Int J Colorectal Dis 2016;31(3):543-51.

Indicizzato‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (apre una nuova finestra)

How I treat cancer-associated anemia. (apre una nuova finestra)

Gilreath JA, Rodgers GM

Fonte‎: Blood 2020;136(7):801-13.

Indicizzato‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (apre una nuova finestra)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (apre una nuova finestra)

Gilreath JA, Stenehjem DD, Rodgers GM.

Fonte‎: J Natl Compr Canc Netw 2012;10(5):669-76.

Indicizzato‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (apre una nuova finestra)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (apre una nuova finestra)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Fonte‎: Eur J Haematol. 2023 110(4):354-61.

Indicizzato‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (apre una nuova finestra)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (apre una nuova finestra)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Fonte‎: Curr Oncol. 2023 24;30(9):7836-51.

Indicizzato‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (apre una nuova finestra)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (apre una nuova finestra)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Fonte‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Indicizzato‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (apre una nuova finestra)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (apre una nuova finestra)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Fonte‎: World J Gastroenterol 2014;20(8):1972-85.

Indicizzato‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (apre una nuova finestra)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (apre una nuova finestra)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Fonte‎: South Asian J Cancer. 2023 15;12(2):93-9.

Indicizzato‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (apre una nuova finestra)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (apre una nuova finestra)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Fonte‎: J Clin Oncol 2008;26(10):1619-25.

Indicizzato‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (apre una nuova finestra)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (apre una nuova finestra)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Fonte‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

Indicizzato‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (apre una nuova finestra)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (apre una nuova finestra)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Fonte‎: Ann Oncol 2013;24(2):475-82.

Indicizzato‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (apre una nuova finestra)

Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions. (apre una nuova finestra)

Van Doren L, Steinheiser M, Boykin K, Taylor KJ, Menendez M, Auerbach M

Fonte‎: Am J Hematol 2024;99(7):1338-48.

Indicizzato‎: PubMed 38282557

DOI‎: 10.1002/ajh.27220

https://pubmed.ncbi.nlm.nih.gov/38282557/ (apre una nuova finestra)

ONCOLOGIA
Gestione dell’anemia
Italiano
Gestione dell’anemia
https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Comitati di assistenza sanitaria (CAS)

Contatti dei rappresentanti locali che danno assistenza gratuita ai medici che devono gestire pazienti testimoni di Geova.

Contatti

Materiale informativo per il personale medico

Alcuni argomenti trattati: strategie cliniche per la gestione dell’emorragia e dell’anemia senza il ricorso all’emotrasfusione, etica e convinzioni religiose dei Testimoni di Geova sui trattamenti medici, servizi offerti dai Testimoni di Geova alla comunità medica grazie alla loro rete internazionale di Comitati di assistenza sanitaria.

Cosa scaricare

Video

Terapie alternative e osservazioni di carattere medico ed etico per medici che hanno in trattamento pazienti testimoni di Geova.

Vedi i video